As for CTLA-4, Ipilimumab, a drug approved by FDA, docked to the MYPPPY motif of CTLA-4 and showed efficacy in inhibiting CTLA-4 in RCC, prostate cancer, cervical cancer, CRC, NSCLC, gastric cancer, pancreatic cancer, ovarian cancer, urothelial cancer, and melanoma [255]. This evidence concerns the gene CTLA4 and familial pancreatic carcinoma.